Biomarker Solutions for Chronic Disease
Biomarker Solutions for Chronic Disease
Chronic Disease
Chronic diseases, such as heart disease, stroke, cancer and diabetes account for approximately 74% of all deaths globally¹ and this is projected to increase by a further 17% in the next 10 years².
This rise in Chronic Disease poses major challenges for healthcare and healthcare systems in the future.
To date, the delivery of precision medicines and their associated companion and complementary diagnostics has been largely in the treatment of cancer. However, many Global Pharma and Biotech companies now recognise the need for earlier identification and treatment for a range of chronic diseases and are developing drugs and diagnostic tests, alongside partners like Almac, to treat these conditions and improve patient outcomes.
Precision Medicine & Chronic Disease
Chronic diseases, such as asthma, chronic obstructive pulmonary disease (COPD), heart failure, chronic kidney disease (CKD), metabolic dysfunction-associated steatohepatitis (MASH), inflammatory bowel disease (IBD) and brain diseases like Alzheimer’s and Parkinson’s affect billions of people worldwide.
These conditions are complex and heterogeneous, often manifesting in diverse ways, which can make accurate diagnosis & appropriate treatment challenging.
Working in tandem with Biopharma clients, Almac are trying to unravel the complex biology underlying various chronic diseases, by applying advanced technologies and robust science to help lead the way in precision medicine. Our aim is to be a key player in revolutionising the diagnosis and treatment of chronic diseases, empowering patients and healthcare providers with effective solutions.
Almac Biomarker Solutions for Chronic Disease
Almac Diagnostic Services has experience supporting biomarker strategies across multiple chronic disease indications. We help Biopharma Partners to develop precision medicine diagnostic solutions for their Biomarker programmes to help identify the right patient populations within clinical trials who should receive novel therapeutics in a targeted way. We aim to bring both drug and diagnostic test towards commercialisation and available in the market for routine clinical practice. Helping patients access new and novel treatments and helping clinicians in the identification and treatment of patients earlier in the chronic disease progression journey and there by reducing the potential future burden on healthcare budgets and systems as a result.
We Offer
Case Studies
Download some of our current Almac Chronic Disease Case Studies.
These case studies are largely anonymised but provide a summary of some of the programmes and experience that Almac Diagnostic Services has been involved in.Case Studies include:
* Renal
* Liver
* Respiratory
* Autoimmune
* Allergy
* IBD
* Brain
Almac Chronic Disease Case Studies
DownloadChronic Disease resources
Including press release and two panel sessions from Professor Richard Kennedy, Global VP of Biomarker Development and Medical Director at Almac Diagnostic Services.
Read now
Almac’s GenomeWeb feature on our CDx collaboration with AstraZeneca in multiple chronic disease indications
GenomeWeb
Read now
Video
Rising to the challenge of delivering precision medicines for Chronic Diseases
World Health summit
Watch Video
Video
Can Precision medicines transform healthcare for chronic Diseases?
Cambridge Science Festival
Why Almac?
Almac offers a unique business model to biotech clients, providing complete flexibility to support the biomarker strategies required to deliver precision medicine, so that you are not tied to one solution and will always have the freedom to change.
A flexible business model
Fee for service
Range of platform & chemistry options
qPCR, NGS, nanoString and others
Multiple disease indications
Oncology and Chronic Diseases
Multiple sample types
Tissue, blood, saliva and a range of others
Global labs
UK, Europe, USA and APAC
Advancing Diagnostics, No Matter The Disease
At Almac we offer a range of biomarker solutions to clients. Our precision medicine approach extends across our portfolio of services and equally applies to oncology, chronic diseases, and rare conditions.
Our commitment to chronic diseases drives us forward. Through precision medicine approaches with multiple partners, we’re helping redefine how we diagnose and treat certain chronic disease conditions. Early detection, personalised therapies, and better outcome are the goals.
NGS solutions
To see our full range of NGS solutions for DNA, RNA and Liquid Biopsy visit our platforms and technologies web section.
Almac also offer Whole Genome Sequencing, Whole Exome Sequencing and Whole Genome Methylation Sequencing for Chronic Disease programmes. Follow the links below.
qPCR and other solutions
As well as NGS solutions Almac also offer a range of qPCR and ddPCR solutions for single gene or multiple gene SNP programmes for Chronic Disease.
To future proof our approach, Almac is constantly reviewing & investing in new technology and chemistry solutions in our labs to offer not only a range of genomic solutions but also move towards epigenetics, cell & gene therapy, single cell sequencing & proteomic offerings. View a list of our current platforms and technologies
- WHO: Non Communicable / Chronic Diseases Key Facts. Sept 2023. Available from: https://www.who.int/news-room/fact-sheets/detail/noncommunicable-diseases
- World Health Organization. Preventing chronic diseases: a vital investment. WHO global report. Geneva: 2005. Available from: https://www.who.int/chp/chronic_disease_report/